|
1
|
Amling CL: Diagnosis and management of
superficial bladder cancer. Curr Probl Cancer. 25:219–278. 2001.
View Article : Google Scholar
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
3
|
Richie JP: Intravesical chemotherapy.
Treatment selection, techniques, and results. Urol Clin North Am.
19:521–527. 1992.PubMed/NCBI
|
|
4
|
Kuroda M, Niijima T, Kotake T, Akaza H and
Hinotsu S: Effect of prophylactic treatment with intravesical
epirubicin on recurrence of superficial bladder cancer - The 6th
Trial of the Japanese Urological Cancer Research Group (JUCRG): a
randomized trial of intravesical epirubicin at dose of 20mg/40ml,
30mg/40ml, 40mg/40ml. Eur Urol. 45:600–605. 2004.
|
|
5
|
Djeu JY and Wei S: Clusterin and
chemoresistance. Adv Cancer Res. 105:77–92. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Luo JH, Xie D, Chen W, et al: Correlation
of clusterin expression to prognosis of bladder carcinoma. Ai
Zheng. 24:743–747. 2005.PubMed/NCBI
|
|
7
|
He LR, Liu MZ, Li BK, et al: Clusterin as
a predictor for chemoradiotherapy sensitivity and patient survival
in esophageal squamous cell carcinoma. Cancer Sci. 1000:2354–2360.
2009.PubMed/NCBI
|
|
8
|
Cheng CY, Cherng SH, Wu WJ, et al:
Regulation of chemosensitivity and migration by clusterin in
non-small cell lung cancer cells. Cancer Chemother Pharmacol.
69:145–154. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Narita S, So A, Ettinger S, et al: GLI2
knockdown using an antisense oligonucleotide induces apoptosis and
chemosensitizes cells to paclitaxel in androgen-independent
prostate cancer. Clin Cancer Res. 14:5769–5777. 2008. View Article : Google Scholar
|
|
10
|
Li M, Gu FL, Li WB, Song YS, Zhou AR and
Guo YL: Introduction of wild-type p53 gene downregulates the
expression of H-ras gene and suppresses the growth of bladder
cancer cells. Urol Res. 23:311–314. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Trougakos IP, So A, Jansen B, Gleave ME
and Gonos ES: Silencing expression of the clusterin/apolipoprotein
j gene in human cancer cells using small interfering RNA induces
spontaneous apoptosis, reduced growth ability, and cell
sensitization to genotoxic and oxidative stress. Cancer Res.
64:1834–1842. 2004. View Article : Google Scholar
|
|
12
|
Lin X, Yu Y, Zhao H, Zhang Y, Manela J and
Tonetti DA: Overexpression of PKCalpha is required to impart
estradiol inhibition and tamoxifen-resistance in a T47D human
breast cancer tumor model. Carcinogenesis. 27:1538–1546. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bettuzzi S, Scorcioni F, Astancolle S,
Davalli P, Scaltriti M and Corti A: Clusterin (SGP-2) transient
overexpression decreases proliferation rate of SV40-immortalized
human prostate epithelial cells by slowing down cell cycle
progression. Oncogene. 21:4328–4334. 2002. View Article : Google Scholar
|
|
14
|
Blaschuk O, Burdzy K and Fritz IB:
Purification and characterization of a cell-aggregating factor
(clusterin), the major glycoprotein in ram rete testis fluid. J
Biol Chem. 258:7714–7720. 1983.PubMed/NCBI
|
|
15
|
Redondo M, Villar E, Torres-Munoz J,
Tellez T, Morell M and Petito CK: Overexpression of clusterin in
human breast carcinoma. Am J Pathol. 157:393–399. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Miyake H, Gleave M, Kamidono S and Hara I:
Overexpression of clusterin in transitional cell carcinoma of the
bladder is related to disease progression and recurrence. Urology.
59:150–154. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xie D, Sham JS, Zeng WF, et al: Oncogenic
role of clusterin overexpression in multistage colorectal
tumorigenesis and progression. World J Gastroenterol. 11:3285–3289.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shannan B, Seifert M, Leskov K, et al:
Clusterin (CLU) and melanoma growth: CLU is expressed in malignant
melanoma and 1,25-dihydroxyvitamin D3 modulates expression of CLU
in melanoma cell lines in vitro. Anticancer Res. 26:2707–2716.
2006.PubMed/NCBI
|
|
19
|
Kruger S, Mahnken A, Kausch I and Feller
AC: Value of clusterin immunoreactivity as a predictive factor in
muscle-invasive urothelial bladder carcinoma. Urology. 67:105–109.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Miyake H, Chi KN and Gleave ME: Antisense
TRPM-2 oligodeoxynucleotides chemosensitize human
androgen-independent PC-3 prostate cancer cells both in vitro and
in vivo. Clin Cancer Res. 6:1655–1663. 2000.PubMed/NCBI
|
|
21
|
July LV, Beraldi E, So A, et al:
Nucleotide-based therapies targeting clusterin chemosensitize human
lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer
Ther. 3:223–232. 2004.PubMed/NCBI
|
|
22
|
So A, Sinnemann S, Huntsman D, Fazli L and
Gleave M: Knockdown of the cytoprotective chaperone, clusterin,
chemosensitizes human breast cancer cells both in vitro and in
vivo. Mol Cancer Ther. 4:1837–1849. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yom CK, Woo HY, Min SY, Kang SY and Kim
HS: Clusterin overexpression and relapse-free survival in breast
cancer. Anticancer Res. 29:3909–3912. 2009.PubMed/NCBI
|
|
24
|
Lamoureux F, Thomas C, Yin MJ, et al:
Clusterin inhibition using OGX-011 synergistically enhances Hsp90
inhibitor activity by suppressing the heat shock response in
castrate-resistant prostate cancer. Cancer Res. 71:5838–5849. 2011.
View Article : Google Scholar
|
|
25
|
Baylot V, Andrieu C, Katsogiannou M, et
al: OGX-427 inhibits tumor progression and enhances gemcitabine
chemotherapy in pancreatic cancer. Cell Death Dis. 2:Oct
20–2011.(Epub ahead of print).
|
|
26
|
Nishitsuji H, Ikeda T, Miyoshi H, Ohashi
T, Kannagi M and Masuda T: Expression of small hairpin RNA by
lentivirus-based vector confers efficient and stable
gene-suppression of HIV-1 on human cells including primary
non-dividing cells. Microbes Infect. 6:76–85. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rubinson DA, Dillon CP, Kwiatkowski AV, et
al: A lentivirus-based system to functionally silence genes in
primary mammalian cells, stem cells and transgenic mice by RNA
interference. Nat Genet. 33:401–406. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen Y, Lin MC, Yao H, et al:
Lentivirus-mediated RNA interference targeting enhancer of zeste
homolog 2 inhibits hepatocellular carcinoma growth through
down-regulation of stathmin. Hepatology. 46:200–208. 2007.
View Article : Google Scholar
|
|
29
|
Manilla P, Rebello T, Afable C, et al:
Regulatory considerations for novel gene therapy products: a review
of the process leading to the first clinical lentiviral vector. Hum
Gene Ther. 16:17–25. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bank A, Dorazio R and Leboulch P: A phase
I/II clinical trial of beta-globin gene therapy for
beta-thalassemia. Ann NY Acad Sci. 1054:308–316. 2005. View Article : Google Scholar : PubMed/NCBI
|
